Company Encyclopedia
View More
name
Novoprotein
688137.SH
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular research and diagnosis, and virus-related products, including antigens, antibodies and test kits. The company also provides protein expression and purification; industrial strain and process development; antibody development and production service; antibody screening and optimization services; and IVT mRNA/circRNA /SaRNA production services.
1.543 T
688137.SHMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking56/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-3.08%D
    • Profit Margin-44.13%E
    • Gross Margin111.10%A
  • Growth ScoreC
    • Revenue YoY9.49%B
    • Net Profit YoY-205.36%E
    • Total Assets YoY-2.16%D
    • Net Assets YoY-2.55%D
  • Cash ScoreC
    • Cash Flow Margin-226.60%D
    • OCF YoY9.49%B
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreA
    • Gearing Ratio5.23%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Novoprotein: Net loss of 24.2236 million yuan in the first half of 2025

    Novoprotein announced that its operating revenue in the first half of 2025 was 72.0946 million yuan, a year-on-year increase of 20.85%. The net loss attributable to shareholders of the listed company was 24.2236 million yuan, compared to a net loss of 8.9058 million yuan in the same period last year. The net cash flow from operating activities was -14.0835 million yuan, compared to 23.2983 million yuan in the same period last year

    Zhitong·
    SH
    688137
    -1.89%
    Zhitong·
    SH
    688137
    -1.89%

    Shareholders of Novoprotein, Heze Qiaobei and Shanghai Pujin, plan to reduce their holdings by no more than 0.61% of the shares

    According to the Zhitong Finance APP, Novoprotein announced that its shareholders Heze Qiaobei and Shanghai Pujin plan to reduce their holdings in the company through centralized bidding and block trading due to their own operational development and funding needs. Among them, Heze Qiaobei plans to reduce its holdings by no more than 162,000 shares (with a planned reduction ratio of no more than 0.2308%), while Shanghai Pujin plans to reduce its holdings by no more than 263,200 shares (with a planned reduction ratio of no more than 0.3750%)

    Zhitong·
    SH
    688137
    -1.89%
    Zhitong·
    SH
    688137
    -1.89%

    Novoprotein: Net loss of 11.8084 million yuan in the first quarter of 2025

    Novoprotein announced that its revenue for the first quarter of 2025 was 33.4446 million yuan, a year-on-year increase of 28.20%; the net loss was 11.8084 million yuan, compared to a net loss of 2.6305 million yuan in the same period last year

    Zhitong·
    SH
    688137
    -1.89%
    Zhitong·
    SH
    688137
    -1.89%

    Novoprotein: Has repurchased 360,300 shares with a total amount of 10.6684 million yuan

    Novoprotein announced that as of March 31, 2025, the company has repurchased 360,300 shares through centralized bidding transactions, accounting for 0.5135% of the total share capital. The highest repurchase price was 35.51 yuan/share, the lowest price was 28.75 yuan/share, and the total payment amounted to 10.6684 million yuan. The repurchase aims to stabilize the stock price, but plans for cancellation and reduction of registered capital have not yet been initiated

    Zhitong·
    SH
    688137
    -1.89%
    Zhitong·
    SH
    688137
    -1.89%

    Novoprotein reported a net loss of 54.8068 million yuan for the fiscal year 2024

    According to the Zhitong Finance APP, Novoprotein released its 2024 annual performance preliminary report, stating that the total operating revenue for 2024 was 127 million yuan, a year-on-year decrease of 16.81%; the net loss attributable to the parent company's owners was 54.8068 million yuan; the net loss attributable to the parent company's owners after deducting non-recurring gains and losses was 72.2141 million yuan; the basic loss per share was 0.78 yuan

    Zhitong·
    SH
    688137
    -1.89%
    Zhitong·
    SH
    688137
    -1.89%
    © 2025 Longbridge｜Disclaimer